Table 3 Receiver operating characteristics for CPS by treatment group.

CPS	Pembrolizumab			SOC			ΔYI
CPS	TPR	FPR	YI	TPR	FPR	YI	ΔYI
0	1.0000	1.0000	0.0000	1.0000	1.0000	0.0000	0.0000
1	0.9444	0.7740	0.1704	0.7600	0.8058	–0.0458	0.2162
10	0.6667	0.4567	0.2099	0.5200	0.5194	0.0006	0.2094
20	0.5833	0.3606	0.2228	0.4400	0.4612	–0.0212	0.2439
30	0.5556	0.3077	0.2479	0.4000	0.3835	0.0165	0.2314
40	0.5556	0.2500	0.3056	0.2800	0.3252	–0.0452	0.3508
50	0.5000	0.2212	0.2788	0.2000	0.2913	–0.0913	0.3701^a
60	0.4722	0.2019	0.2703	0.2000	0.2379	–0.0379	0.3082
70	0.3056	0.1538	0.1517	0.1200	0.1845	–0.0645	0.2162
80	0.2222	0.1058	0.1165	0.1200	0.1456	–0.0256	0.1421
90	0.0833	0.0769	0.0064	0.0800	0.1165	–0.0365	0.0429
100	0.0556	0.0240	0.0315	0.0000	0.0583	–0.0583	0.0898
—	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000

∆YI change in Youden index, CPS combined positive score, FPR false-positive rate, TPR true-positive rate, YI Youden index.
^aLargest difference in YI.

Quick links

Search